Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?

被引：35

作者：

Holmes, J. A. ^{[1
]}

Desmond, P. V. ^{[1
]}

Thompson, A. J. ^{[1
,2
,3
]}

机构：

[1] Univ Melbourne, St Vincents Hosp, Dept Gastroenterol, Fitzroy, Vic 3065, Australia

[2] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia

[3] Duke Univ, Med Ctr, Duke Clin Res Inst, Dept Gastroenterol, Durham, NC USA

来源：

JOURNAL OF VIRAL HEPATITIS | 2012年 / 19卷 / 10期

关键词：

hepatitis C virus; IL28B polymoprhism; NS3; protease; NS5a protein; NS5b polymerase; sustained virological response; SUSTAINED VIROLOGICAL RESPONSE; INTERLEUKIN; 28B; SPONTANEOUS CLEARANCE; COST-EFFECTIVENESS; GENETIC-VARIATION; VIRAL KINETICS; VIRUS; POLYMORPHISM; RIBAVIRIN; TELAPREVIR;

D O I：

10.1111/jvh.12003

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

IL28B genotype has been shown to be the strongest pretreatment predictor of sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C infection (CHC) treated with pegylated interferon (peg-IFN) and ribavirin (RBV). Patients carrying the good response genotype have a two- to threefold higher chance of SVR than those with a poor response genotype, manifest as dramatically improved early viral kinetics. However, the treatment paradigm for CHC is changing with the introduction of potent direct-acting antivirals (DAAs). IL28B genotype remains relevant to both telaprevir and boceprevir treatment regimens, although the strength of association with virological response is attenuated. The association between IL28B genotype and outcomes of treatment regimens that involve peg-IFN plus combination DAA therapy, or IFN-free regimens, is currently being evaluated. IL28B genotype may remain relevant to individualizing the choice of treatment regimen in the future.

引用

页码：677 / 684

页数：8

共 48 条

[1] IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C [J].

Asselah, Tarik ;

De Muynck, Simon ;

Broet, Philippe ;

Masliah-Planchon, Julien ;

Blanluet, Maud ;

Bieche, Ivan ;

Lapalus, Martine ;

Martinot-Peignoux, Michelle ;

Lada, Olivier ;

Estrabaud, Emilie ;

Zhang, Qian ;

El Ray, Ahmed ;

Vidaud, Dominique ;

Ripault, Marie-Pierre ;

Boyer, Nathalie ;

Bedossa, Pierre ;

Valla, Dominique ;

Vidaud, Michel ;

Marcellin, Patrick .

JOURNAL OF HEPATOLOGY, 2012, 56 (03) :527-532

[2] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[3] IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C [J].

Bochud, P. -Y. ;

Bibert, S. ;

Negro, F. ;

Haagmans, B. ;

Soulier, A. ;

Ferrari, C. ;

Missale, G. ;

Zeuzem, S. ;

Pawlotsky, J. -M. ;

Schalm, S. ;

Hellstrand, K. ;

Neumann, A. U. ;

Lagging, M. .

JOURNAL OF HEPATOLOGY, 2011, 55 (05) :980-988

[4] Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C [J].

Camma, Calogero ;

Petta, Salvatore ;

Enea, Marco ;

Bruno, Raffaele ;

Bronte, Fabrizio ;

Capursi, Vincenza ;

Cicchetti, Americo ;

Colombo, Giorgio L. ;

Di Marco, Vito ;

Gasbarrini, Antonio ;

Craxi, Antonio .

HEPATOLOGY, 2012, 56 (03) :850-860

[5] Interleukin-28B Polymorphisms Are Associated With Histological Recurrence and Treatment Response Following Liver Transplantation in Patients With Hepatitis C Virus Infection [J].

Charlton, Michael R. ;

Thompson, Alexander ;

Veldt, Bart J. ;

Watt, Kym ;

Tillmann, Hans ;

Poterucha, John J. ;

Heimbach, Julie K. ;

Goldstein, David ;

McHutchison, John .

HEPATOLOGY, 2011, 53 (01) :317-324

[6] Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-a and ribavirin [J].

Chen, Y. ;

Xu, H. -X. ;

Wang, L. -J. ;

Liu, X. -X. ;

Mahato, R. I. ;

Zhao, Y. -R. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (02) :91-103

[7] Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C [J].

Chu, Tom W. ;

Kulkarni, Rohit ;

Gane, Edward J. ;

Roberts, Stuart K. ;

Stedman, Catherine ;

Angus, Peter W. ;

Ritchie, Brett ;

Lu, Xiao-Yu ;

Ipe, David ;

Lopatin, Uri ;

Germer, Soren ;

Iglesias, Victor A. ;

Elston, Robert ;

Smith, Patrick F. ;

Shulman, Nancy S. .

GASTROENTEROLOGY, 2012, 142 (04) :790-795

[8] Donor and Recipient IL28B Polymorphisms in HCV-Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation [J].

Coto-Llerena, M. ;

Perez-del-Pulgar, S. ;

Crespo, G. ;

Carrion, J. A. ;

Martinez, S. M. ;

Sanchez-Tapias, J. M. ;

Martorell, J. ;

Navasa, M. ;

Forns, X. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (05) :1051-1057

[9] Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 [J].

De Nicola, Stella ;

Aghemo, Alessio ;

Rumi, Maria Grazia ;

Galmozzi, Enrico ;

Valenti, Luca ;

Soffredini, Roberta ;

De Francesco, Raffaele ;

Prati, Gian Maria ;

D'Ambrosio, Roberta ;

Cheroni, Cristina ;

Donato, Maria Francesca ;

Colombo, Massimo .

HEPATOLOGY, 2012, 55 (02) :336-342

[10] Relationship Between the Interleukin-28b Gene Polymorphism and the Histological Severity of Hepatitis C Virus-Induced Graft Inflammation and the Response to Antiviral Therapy After Liver Transplantation [J].

Eurich, Dennis ;

Boas-Knoop, Sabine ;

Ruehl, Martin ;

Schulz, Maria ;

Carrillo, Esperanza D. ;

Berg, Thomas ;

Neuhaus, Ruth ;

Neuhaus, Peter ;

Neumann, Ulf Peter ;

Bahra, Marcus .

LIVER TRANSPLANTATION, 2011, 17 (03) :289-298

← 1 2 3 4 5 →